

Applicants: Francis G. Fang and Shiping Xie  
Serial No.: 09/903,101  
Filed: 11, 2001  
Page 8



RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

Remarks

Claims 3 were pending in the subject application. By this amendment, applicants have canceled claims 1 and 3, added new claim 4 and amended claim 2. Accordingly, claims 2 and 4 are currently pending.

Support for amended claim 2 can be found inter alia in the specification, as originally filed, on pages 3-6.

Support for new claim 4 can be found inter alia in the specification, as originally filed, on pages 3-6 and page 9.

Restriction Requirement

In the Restriction Requirement issued on May 8, 2002, the Examiner required restriction to one of the following allegedly distinct inventions as follows:

- I. Claim 1, drawn to a process of preparing compounds of formula I from formula II.
- II. Claim 3, drawn to compounds.
- III. Claim 2, drawn to compounds which are not encompassed by claim 3.

In response, applicants elect Group III, without traverse.

Applicants have amended claim 2, to remove the compounds of claim 3 from the scope of the claim. Applicants have also removed compounds of formulas (III) and (VI) from claim 2 and have moved compounds of formula (IV) to new claim 4.


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number

Applicants: Francis G. Fang and Shiping Xie  
Serial No.: 09/903,101  
Filed : July 11, 2001  
Page 9

provided below.

No fee is deemed necessary in connection with the filing of this Amendment and Response to Restriction Requirement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.




Respectfully submitted,




John P. White  
Registration No. 28,678  
Gary J. Gershik  
Registration No. 39,992  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, DC 20231.	
<i>Gary J. Gershik</i>	<i>6/7/02</i>
John P. White	Date
Reg. No. 28,678	
Gary J. Gershik	
Reg. No. 39,992	

2. (Amended) A compound of formulas (II), (III), (IV), or (V):





wherein:

$R_1$  is selected from hydrogen, lower alkyl,  $(C_{3-7})$ cycloalkyl,  $(C_{3-7})$ cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, or alkoxy alkyl;

$R_4$  and  $R_2$ , which may be the same or different, are independently is selected from hydrogen, lower alkyl,  $(C_{3-7})$ cycloalkyl,  $(C_{3-7})$ cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, or alkoxy alkyl, or  $(-CH_2NR_8R_8)$ , wherein:

i)  $R_7$  and  $R_8$ , which may be the same or different, are independently selected from hydrogen, lower alkyl,  $(C_{3-7})$  cycloalkyl,  $(C_{3-7})$  cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, or lower alkoxy lower alkyl; or

ii)  $R_7$  represents hydrogen, lower alkyl,  $(C_{3-7})$ cycloalkyl,  $(C_{3-7})$  cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, or lower alkoxy lower alkyl, and  $R_8$  represents  $-COR_9$ ,

wherein:

$R_9$  represents hydrogen, lower alkyl, perhalo-lower alkyl,  $(C_{3-7})$ cycloalkyl,  $(C_{3-7})$  cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, lower

alkoxy, lower alkoxy lower alkyl; or

iii)  $R_7$  represents hydrogen or lower alkyl; and  $R_8$  represents diphenyl-methyl or  $-(CH_2)_t$  Ar

wherein:

$t$  is 0 to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl optionally substituted with one or more substituents selected from hydroxy, methyl, halogen, and amino; or

iv)  $R_7$  and  $R_8$  taken together with the linking nitrogen form a saturated 3 to 7 atom heterocyclic group of formula (IA)



(IA)

wherein:

Y represents O, S, SO, SO<sub>2</sub>, CH<sub>2</sub> or NR<sub>10</sub>,


wherein:

$R_{10}$  represents hydrogen, lower alkyl, perhalo lower alkyl, aryl, aryl substituted with one or more substituents selected from lower alkyl, lower alkoxy, halogen, nitro, amino, lower alkyl amino, perhalo-lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl groups or  $-COR_{11}$ ,

wherein:

$R_{11}$  represents hydrogen, lower alkyl, perhalo-lower alkyl, lower alkoxy, aryl, aryl substituted with one or more substituents selected from lower alkyl, perhalo-lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl groups; or

$R_3$  and  $R_4$  are independently selected from hydrogen, lower alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, or alkoxy alkyl; or  $R_3$  and  $R_4$  taken together form a saturated 5 to 6 atom heterocyclic group of formula (IB)



wherein,

$n$  represents the integer 1 or 2; or

$R_3$  represents  $-OCONR_{12}R_{13}$ ,

wherein,


$R_{12}$  and  $R_{13}$ , which may be the same or different, are independently selected from hydrogen, a substituted or unsubstituted alkyl group with 1-4 carbon atoms or a substituted or unsubstituted carbocyclic or heterocyclic group, with the proviso that when both  $R_{12}$  and  $R_{13}$  are substituted or unsubstituted alkyl groups, they may be combined together with the nitrogen atom, to which they are bonded, to form a heterocyclic ring which may be interrupted with  $-O-$ ,  $-S-$  and/or  $>N-R_{14}$  in which  $R_{14}$  is hydrogen, a substituted or unsubstituted alkyl group with 1-4 carbon atoms or a substituted or unsubstituted phenyl group;<sup>2</sup> and

$R_5$  represents hydrogen or alkyl; and

$R_6$  represents hydrogen or alkyl, and

or a pharmaceutically acceptable salts thereof.

4. (New) A compound of formula (IV);



(IV)

wherein:

X represents triflate or halo;

R<sub>1</sub> and R<sub>2</sub>, which may be the same or different, are independently selected from hydrogen, lower alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, or alkoxy alkyl, or (-CH<sub>2</sub>NR<sub>2</sub>), wherein:

i) R<sub>7</sub> and R<sub>8</sub>, which may be the same or different, are independently selected from hydrogen, lower alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, or lower alkoxy lower alkyl; or

ii) R<sub>7</sub> represents hydrogen, lower alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, or lower alkoxy lower alkyl, and R<sub>8</sub> represents -COR<sub>9</sub>,

wherein:

R<sub>9</sub> represents hydrogen, lower alkyl, perhalo-lower alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, lower

alkoxy, lower alkoxy lower alkyl; or

iii) R<sub>7</sub> represents hydrogen or lower alkyl; and R<sub>8</sub> represents diphenyl-methyl or – (CH<sub>2</sub>)<sub>t</sub>, Ar

wherein:

t is 0 to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl optionally substituted with one or more substituents selected from hydroxy, methyl, halogen, and amino; or

iv) R<sub>7</sub> and R<sub>8</sub> taken together with the linking nitrogen form a saturated 3 to 7 atom heterocyclic group of formula (IA)



wherein:

Y represents O, S, SO, SO<sub>2</sub>, CH<sub>2</sub>, or NR<sub>10a</sub>

wherein:

R<sub>10a</sub> represents hydrogen, lower alkyl, perhalo lower alkyl, aryl, aryl substituted with one or more substituents selected from lower alkyl, lower alkoxy, halogen, nitro, amino, lower alkyl amino, perhalo-lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl groups or –COR<sub>11a</sub>

wherein:

R<sub>11a</sub> represents hydrogen, lower alkyl, perhalo-lower alkyl, lower alkoxy, aryl, aryl substituted with one or more substituents selected from lower alkyl, perhalo-lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl groups;



R<sub>3</sub> represents -OCONR<sub>12</sub>R<sub>13a</sub>

wherein,

R<sub>12</sub> and R<sub>13</sub>, which may be the same or different, are independently selected from hydrogen, a substituted or unsubstituted alkyl group with 1-4 carbon atoms or a substituted or unsubstituted carbocyclic or heterocyclic group, with the proviso that when both R<sub>12</sub> and R<sub>13</sub> are substituted or unsubstituted alkyl groups, they may be combined together with the nitrogen atom, to which they are bonded, to form a heterocyclic ring which may be interrupted with -O-, -S- and/or -N-R<sub>14</sub> in which R<sub>14</sub> is hydrogen, a substituted or unsubstituted alkyl group with 1-4 carbon atoms or a substituted or unsubstituted phenyl group;

R<sub>4</sub> is selected from hydrogen, lower alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>) cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, or alkoxy alkyl;

R<sub>5</sub> represents hydrogen or alkyl; and

R<sub>6</sub> represents hydrogen or alkyl,

or a pharmaceutically acceptable salt thereof